The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
April 17th 2024
Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Diabetes Risk Factors Dominate Top Causes of Global Mortality, Heighten COVID-19 Risks
October 15th 2020New data estimates from the Global Burden of Disease Study published by The Lancet illustrate how rising rates of chronic disease and public health failures compounded over decades to worsen the coronavirus disease 2019 (COVID-19) pandemic.
Read More
Can an HIV Drug Help Prevent Diabetes?
October 12th 2020Patients who received anti-inflammasome nucleoside reverse-transcriptase inhibitors (NRTIs)—drugs approved to treat HIV-1 and hepatitis B infections—exhibited a 33% reduced risk of developing type 2 diabetes (T2D), according to a meta-analysis published in Nature Communications.
Read More
Diabetes Drug May Hold Potential as COVID-19 Treatment
September 29th 2020In patients with type 2 diabetes admitted to the hospital for coronavirus disease 2019 (COVID-19), treatment with sitagliptin at the time of hospitalization was associated with reduced mortality and improved clinical outcomes compared with standard-of-care treatment.
Read More
Progress Made in Diabetes Technology Coverage, Access Among Medicare Beneficiaries
September 28th 2020Recently, 2 district courts secured a pair of victories for Medicare beneficiaries who use continuous glucose monitor technologies to manage their diabetes, while senators introduced bipartisan legislation aimed at increasing access to the Medicare Diabetes Prevention Program.
Read More
Ertugliflozin CV Outcomes in T2D Population Are Similar to Placebo
September 23rd 2020In patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease, results from a multicenter, double-blind trial show that treatment with ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events.
Read More
Phase 2 Trial Shows Weekly Insulin Injection Outcomes Similar to Daily Injections for T2D
September 22nd 2020In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100.
Read More
Exercise Amount Impacts A1C Reduction in T2D Population, Study Finds
September 18th 2020A higher volume of exercise training may improve glycemic control more in individuals with type 2 diabetes (T2D) compared with individuals who exercise less frequently, according to a stud in Medicine & Science in Sports & Exercise.
Read More
The Role of SGLT-2 Inhibitors in Heart Failure: A Roundtable Discussion
September 18th 2020The American Journal of Managed Care® recently hosted a Peer Exchange that featured discussion among a panel of expert cardiologists and managed care decision makers regarding how cardiovascular outcome trial results are impacting the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure and how these drugs are shaping heart failure outcomes for patients. Panelists were Nihar R. Desai, MD, MPH, assistant professor of medicine in the cardiovascular medicine section of the Yale School of Medicine and investigator in the Center for Outcomes Research and Evaluation in New Haven, Connecticut; Jaime Murillo, MD, national senior director of cardiology at UnitedHealthcare in Fort Lauderdale, Florida; and Steven Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Cleveland, Ohio. The moderator was Neil B. Minkoff, MD, chief medical officer of Coeus Consulting Group in Sudbury, Massachusetts.
Read More
The Role of SGLT-2 Inhibitors in Heart Failure: An Interview With Darren K. McGuire, MD, MHSc
September 18th 2020An editor from The American Journal of Managed Care® spoke with Darren K. McGuire, MD, MHSc, to discuss the impact of the results of cardiovascular outcome trials on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure in real-world clinical practice. McGuire is professor of medicine, director of the cardiology clinical trials unit, and director of the Parkland Hospital and Health System outpatient cardiology clinics at the University of Texas Southwestern Medical Center in Dallas.
Read More
Study Finds Peer Mentor Interventions Ineffective Among Veterans With T2D
September 14th 2020Peer mentor interventions did not improve long-term hemoglobin A1C levels or yield sustained benefits among veterans with poorly controlled type 2 diabetes (T2D), according to study results published in JAMA Network Open.
Read More